Background: B-type Natriuretic Peptide (BNP) a neurohormone synthesized in ventricular myocardium and released into the circulation in response to ventricular dilatation and pressure overload, is a current biomarker used for identifying patients at high risk of Acute Coronary Syndrome (ACS). High level of BNP is associated with an increased risk of Major Adverse Cardiac Events (MACE) including new or progressive heart failure and myocardial infarction. The objective of this study was to assess the prognosis of newly diagnosed ACS patients by using plasma BNP level. Methods: This study was conducted in the department of Biochemistry, Bangabandhu Sheikh Mujib Medical University (BSMMU) in collaboration with National Institute of Cardiovascular Disease (NICVD) from January 2013 to December 2013. Total 100 newly diagnosed ACS patients, aged 30 to 70 years, irrespective of sex who reported within 24 hours of onset of symptoms were enrolled in this study by purposive and convenient sampling. Plasma BNP level of selected study subjects was measured within 24 hours of onset of symptoms. Then subjects were grouped on the basis of their empirical cut-off value of plasma BNP concentration Group I having plasma BNP level <135 pg/mL and Group II having plasma BNP level 135 pg/mL. Results: Of 100 ACS patients, 86 were male and 14 were female with the mean age 49.61±10.28 years and the age range of 30 to 70 years. Among 26 patients in Group I, good recovery, morbidity and mortality were 22 (84.6%), 4 (15.4%) and zero and among 74 patients in Group II good recovery, morbidity and mortality were 18 (24.3%), 53 (71.6%) and 3 (3.0%) respectively. Differences in outcome between groups were statistically significant (P=0.001). Above the empirical cut-off value of BNP (135 pg/mL) good prognosis was for 18 (24.3%) and bad prognosis was for 56 (75.7 %) patients and relative risk 3.48 in 95% CI (2.25-5.36). Conclusion: It can be concluded from this study that higher baseline plasma BNP concentration is associated with more adverse clinical outcomes in ACS patients. Since the baseline plasma BNP concentrations at the onset of event shows incremental prognostic value, so plasma BNP can be used clinically as a biomarker of prognosis in ACS patients.
INTRODUCTION
Acute Coronary Syndrome (ACS) refers to a group of cardiac disorders including Unstable Angina (UA), ST-elevation Myocardial Infarction (STEMI) and Non STElevation Myocardial Infarction (NSTEMI) attributed to the various degree of ischemia 1 .
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MATERIALS AND METHODS
This prognostic cohort study was carried out in the department of Biochemistry, Bangabandhu Sheikh Mujib Medical University (BSMMU), in collaboration with National Institute of Cardiovascular Disease (NICVD) from January 2013 to December 2013. Total 100 newly diagnosed ACS patients, aged 30 to 70 years, irrespective of sex who reported within 24 hours of symptom onset were enrolled in the study by purposive and convenient sampling. The purpose and procedure of the study were discussed with the subjects who fulfilled the enrollment criteria. Patients who had history of previous ischemic heart disease, heart failure, severe renal failure, severe liver disease and thyroid disorder were excluded from the study. Written informed consent was taken from those who agreed to participate in the study. Plasma BNP level was measured within 24 hours of symptom onset of selected study subjects. Data were collected from the selected subjects on variables of interest using a data collection sheet by interview, observation, clinical examination, serological investigations and from the history sheet of the patients. After measurement of plasma BNP concentration subjects were grouped on the basis of their empirical cut-off value of plasma BNP concentration. Group I included subjects having plasma BNP level <135 pg/mL and Group II having plasma BNP level 135 pg/mL. Then all patients were treated and managed by conventional standard management protocol during their hospital stay and up to 3 months. Prognosis was assessed by a review of medical records, and follow-up telephone interview. Follow-up time was defined as the time from admission to the first cardiac event or, for patient without an event, from admission up to 3 months. During hospital stay and during their follow-up period, patients were assessed clinically for any kind of clinical outcomes like good recovery, morbidity (like recurrent MI, heart failure, arrhythmia, cardiogenic shock, coronary stenosis where revascularization was needed) and mortality. 
RESULTS
Among the 100 ACS patients 86 were male and 14 were female with the mean age 49.61±10.28 years and the age range of 30 to 70 years. 3 . The prevalence of coronary heart disease in Bangladesh was found to be 33 per 10000 in 1976, which has increased more than five-fold to be 172 per 10000 in 1998 4 . In the inter-heart study, Bangladesh has the highest prevalence of most risk factors compared to people in other South Asian countries 5 .
The pathogenesis of ACS involves an intricate interplay among the endothelium, the inflammatory cells and the thrombogenecity of blood 6 . Coronary atherosclerosis complicated by plaque rupture (fissure) and subsequent thrombosis is the main cause of acute ischemic syndromes 7 . Approximately 75% of all coronary thrombi responsible for ACS are precipitated by plaque rupture 8 . After either plaque rupture or endothelial erosion, the subendothelial matrix (which is rich in tissue factor, a potent procoagulant) is exposed to the circulating blood; this exposure leads to platelet adhesion followed by platelet activation and aggregation and the subsequent formation of a thrombus 9 . Current biomarkers used for identifying patients at high risk of ACS primarily include biomarkers of myocardial necrosis (troponin, CK-MB, myoglobin), or ischemia and myocardial stretch (BNP) 10 . Brain natriuretic peptide (BNP) is a 32-aminoacid neurohormone synthesized in ventricular myocardium and released into the circulation in response to ventricular dilatation and pressure overload, first identified in extracts of porcine brain 11 . BNP belongs to the natriuretic peptide family. It comprises structurally similar peptides atrial natriuretic peptide (ANP), BNP, C-type natriuretic peptide (CNP) and Dtype natriuretic peptide. BNP expression and release from cardiomyocites can also be stimulated by a variety of endocrine, paracrine and autocrine factors 12 . The plasma level of BNP is elevated in patients with congestive heart failure and increases in proportion to the degree of left ventricular dysfunction and the severity of symptoms of heart failure 13 . After acute myocardial infarction, levels of BNP rise rapidly during the first 24 hours and then tend to stabilize. Measurement of the level of BNP between one and four days after a transmural infarction provides prognostic information that is independent of the left ventricular ejection fraction and other important base-line variables 12 
.
In one study high level of BNP was found associated with an increased risk of major adverse cardiac events (MACE) including new or progressive heart failure and myocardial infarction 14 . The mortality and morbidity in ACS is high due to lack of reliable and accurate scale of risk stratification following the onset of events. Therefore we designed this study to assess the prognosis of newly diagnosed ACS patients by using BNP, and thereby take appropriate therapeutic regimen to prevent further complications. Among the study subjects 26 were in Group I (plasma BNP value <135.0 pg/mL) and 74 in Group II (plasma BNP value >135.0 pg/mL). Out of total ACS patients, 65 had ST-elevation myocardial infarction (STEMI), 30 had non ST-elevation myocardial infarction (NSTEMI) and rest 5 had unstable angina (UA) (Fig 1) . The importance of cardiac marker concentration (BNP) in relation to prognosis of ACS patients is described in The prognostic outcome of ACS patient in relation to plasma BNP level is described in Table 3 . In Group I among 26 patients good recovery, morbidity and mortality were found 22 (84.6%), 4 (15.4%) and 0 (0.0%) and in Group II among 74 patients good recovery, morbidity and mortality were found 18 (24.3%), 53 (71.6%) and 3 (3.0%) respectively. In Group II we found significantly low good recovery but high morbidity and mortality compared with Group I (p=0.001).
BNP Prognosis
Group I Group II p value (<135 pg/mL) (>135 pg/mL) Number (%) Number (%) 
DISCUSSION
Coronary Heart Disease (CHD) is the leading cause of mortality and morbidity affecting millions of peoples in both developed and developing countries. Clinical criteria, electrocardiographic criteria and conventional laboratory tests do not adequately predict the risk of cardiovascular events in patients presenting with ACS. Plasma BNP concentration of all study subjects were measured at enrollment and then divided into two groups on the basis of empirical cut-off value (Group I having plasma BNP level <135 pg/mL and Group II having plasma BNP level 135 pg/mL). The study subjects of two groups were identical irrespective of sex, history of smoking, hypertension and diabetes but age was significantly higher in Group II (p=0.037). Similar findings were observed by them 15 . In multiple linear regression analysis they showed that Nterminal pro-BNP (NT pro-BNP) concentration was mainly associated with age. They also found increased BNP level in female. But in this study we did not find any relationship with the sex. Our finding is consistent with them where they also did not find any significant difference in BNP levels between male and female 16 . We have found the significant bad outcomes in subjects having increased BNP levels (p=0.001). In our study correlation of prognosis like good and bad outcomes with BNP was statistically significant (Table 5 ). The relative risk of subjects having higher BNP level was found 3.48 at 95% CI (2.25-5.36). Higher bad clinical outcomes in Group II compared with Group I indicate that the increasing baseline plasma BNP concentration is associated with worsening clinical outcomes. This result is consistent with them 16 . In their multivariate analysis, they showed that BNP was the independent predictive value for 7 days' categorical outcome in patients admitted with chest pain (Logistic regression p=0.001, R square=0.741). Our findings are also consistent with findings of them 11 . They demonstrated that a single measurement of plasma BNP levels provides powerful information for use in risk stratification across the entire spectrum of ACS. They found that increasing quartiles of plasma NT pro-BNP was associated with a greater risk of death or cardiovascular events, with annual event rate 2.6% in the lowest quartile to annual event rate 19.6% in highest quartile 17 . That means elevated level of plasma NT pro-BNP in ACS predicts cardiovascular morbidity and mortality independent of other prognostic markers. Another study found that baseline BNP level higher than 80 pg/mL was associated with 2-fold higher long term risk of death (adjusted hazard ratio [HR], 2.1; 95% CI). They also observed that high levels of BNP during ACS strongly predict risk for death and incident congestive heart failure (HR 2.5) 18 . In our study prognostic outcomes of the study subjects were seen according to the concentration of BNP. We found that with increasing concentrations of BNP, morbidity and mortality also increased. Increasing in BNP concentrations with morbidity and mortality was statistically significant (p=0.001). They found this type of findings in their study 19 . They found the proportion of men with NT pro-BNP concentrations between 100 and 399 ng/L was significantly lower than the proportion with concentrations <100 ng/L, it was, however, significantly higher in small group with NT pro-BNP 2000 ng/L (p=0.001 and p=0.026 by logistic regression, respectively). Spearman rank correlation test of serum BNP with prognosis showed r value=0.488 and p value=0.001. Prognosis is significantly correlated with concentration of biomarker (Fig 2) . In a study they demonstrated that baseline plasma BNP >80 pg/mL was associated with a 2-fold higher long term risk of death (adjusted hazard ratio 2.1) 18 . They found that on multivariant analysis, a baseline BNP level of >80 pg /mL was still associated with a near 3-fold higher long term risk of CV events (adjusted Relative Risk [RR] 2.63 (95% CI 1.34 5.19) 20 . The findings of our study suggest that BNP should be measured after an ACS in order to identify patients at high and low risk for adverse outcomes and treatment should be adjusted accordingly.
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CONCLUSION
From this study it can be concluded that higher baseline plasma BNP concentration is associated with more adverse clinical outcomes in ACS patients.
Since the baseline plasma BNP concentrations at the onset of event shows incremental prognostic value, plasma BNP can be used clinically as a biomarker of prognosis in ACS patients.
LIMITATIONS OF THE STUDY
Our sample size was small and repeated evaluations of BNP levels at subsequent intervals could not be done. Further studies with large sample size and repeated evaluations of BNP are recommended.
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